ESMO 2018 VL

Targeting Treatment to Subtypes in Prostate Cancer - Misha Beltran

Details
Misha Beltran and Alicia Morgans discuss treatment selection for patients with unique molecular subtypes. They discuss the use of ADT in this patient population as well as chemotherapy. Interestingly, they highlight the shared alteration and learnings from the study of small cell lung cancer. Biographies: Himisha Beltran, MD, Medical Oncologist, Dana Farber Cancer Institute, Harvard Medical School...

The Use of Molecular Profile in Renal Cancer - Martin Voss

Details
(Length of Discussion: 10 min) Daniel George and Martin Voss discuss the evolving management of patients with advanced renal cell carcinoma with a focus on the genomic landscape in high risk localized disease. Based on molecular profiles, we may be able to prognosticate more accurately on their risk for recurrence. Applicability of this biomarker data will guide the future in appropriate therapeut...

Decision Making When Treating Prostate Cancer - Silke Gillessen

Details
Silke Gillessen and Alicia Morgans discuss the need to be proactive with bone health in this patient population. In addition, Silke shares topics that will be discussed at the 2019 Advanced Prostate Cancer Consensus Meeting (APCCC). Biographies: Silke Gillessen, MD, Professor Medical Oncology, University of Berne, Switzerland. Co-founder of the Advanced Prostate Cancer Consensus Conference (APCCC)...

Quality of Life and Health Economics Data: STAMPEDE Trial - Nick James

Details
Nick James and Alicia Morgans discuss the quality of life and health economics data from the docetaxel part of the STAMPEDE trial. They also review data presented by Chris Parker on the use of radiotherapy to the primary tumor for men with newly-diagnosed metastatic prostate cancer. Biographies: Professor Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D., Institute of Cancer and Genomic Sciences NIHR...

ERA 223: Presentation Summary from ESMO 2018 - Fred Saad

Details
(Length of Presentation: 8 min) Fred Saad presents: Abiraterone Acetate and Prednisone in Combination with Radium-223 or Placebo in Patients with Castration-Resistant Prostate Cancer in Bone Metastases: The Results of the Phase Three Trial. Biography: Fred Saad, MD FRCS, Full Professor and Chief of Urologic Oncology, Medical Director of Interdisciplinary Urologic Oncology Group, and Department of...

The Role of Bone Health Agents in Patients with Prostate Cancer - Tia Higano

Details
(Length of interview: 11 minutes) Tia Higano and Alicia Morgans share their perspective on the data analysis from the ERA-223 phase III study and highlight the value of incorporating bone health management, weight-bearing and resistance exercise when treating patients with prostate cancer. Biographies: Celestia (Tia) S. Higano, MD, Director, Prostate Cancer Clinical Research Group, Seattle Cancer...

EXTEND, Phase 2 Trial Evaluating the Safety and Efficacy of Exercise Training in Men with Hormone Naïve Prostate Cancer - Mike Harrison

Details
(Length of interview: 16 min) Mike Harrison and Chuck Ryan dialogue on the specifics of the EXTEND trial. This is a phase 2 trial evaluating the safety and efficacy of exercise training in men receiving enzalutamide plus conventional ADT for hormone naïve prostate cancer. The discussion ensues to the value of exercise in this patient population and some of the nuances in managing patients in this...

Update on Immunotherapy Advances in Renal and Bladder Cancer - Cora Sternberg

Details
(Length of interview: 17 min) Cora Sternberg and Alicia Morgans provide a review of immunotherapy advances in both renal cell and bladder cancer. They review past and current trials providing insights into potential clinical and treatment applications. Biographies: Cora Sternberg MD, FACP Clinical Director of the Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, Former Chi...

A Renewed Analysis of ERA 223 - Fred Saad

Details
Charles Ryan and Fred Saad discuss the recent analysis of data points from ERA 223. (Length of Interview: 4 min) Biographies: Fred Saad, MD FRCS, Full Professor and Chief of Urologic Oncology, Medical Director of Interdisciplinary Urologic Oncology Group, Department of Surgery/Faculty of Medicine; Institut du cancer de Montréal/CRCHUM Charles J. Ryan, MD Referenced in this discussion: ERA 223 - A...

ESMO Featured Presentations - Tom Keane

Details
(Length of Video: 5 min) Tom Keane provides highlights from late-breaking abstracts and state-of-the-art lectures to be presented at ESMO 2018 in prostate, bladder and kidney cancer Biography: Thomas E. Keane, MBBCh, FRCSI, FACS Related Content: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous...